CORESTEMCHEMON Inc. (KOSDAQ:166480)
South Korea · Delayed Price · Currency is KRW 2,125.00
+55.00 (2.66%)
At close: Sep 23, 2026
CORESTEMCHEMON Revenue
CORESTEMCHEMON had revenue of 5.40B KRW in the quarter ending June 30, 2026, a decrease of -1.73%. This brings the company's revenue in the last twelve months to 18.29B, down -26.34% year-over-year. In the year 2025, CORESTEMCHEMON had annual revenue of 20.16B, down -29.91%.
Revenue (ttm)
18.29B
Revenue Growth
-26.34%
P/S Ratio
5.15
Revenue / Employee
508.11M
Employees
36
Market Cap
94.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.16B | -8.60B | -29.91% |
| Dec 31, 2024 | 28.76B | -4.89B | -14.54% |
| Dec 31, 2023 | 33.66B | -12.22B | -26.64% |
| Dec 31, 2022 | 45.88B | 15.64B | 51.71% |
| Dec 31, 2021 | 30.24B | 3.88B | 14.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Cell Biotech | 60.40B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Prestige Biologics | 26.67B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 19.53B |
| EyeGene | 4.48B |
| Y-Biologics | 3.17B |